Opus Genetics is a Research Triangle Park, North Carolina-based clinical-stage biopharmaceutical company developing gene therapies for inherited retinal diseases (IRDs)

Fund Snapshot Firm Jeito Capital Fund I Jeito I, €534M ($630M), final close September 2021 Fund II Jeito II, >

Understanding the instrument that sits behind every major royalty fund's capital structure and every commercial-stage biotech's liquidity toolkit — how revolvers work, why they matter, and how they interact with royalty financing transactions.

When two pharmaceutical companies or a biotech and a royalty fund negotiate a royalty agreement, the headline debate is almost

The conversation about emerging markets in pharmaceutical royalties runs a predictable circuit. China dominates the headlines, Korea is gaining ground,

April 5–10, 2026 saw $9.2 billion in confirmed capital deployed across biopharma, spanning 6 M&A transactions,

The term "Royalty Interest Agent" does not appear as a standardised designation in pharmaceutical royalty financing documentation. Instead,

Coefficient Bio was a New York-based stealth AI-biotech startup founded in September 2025. On April 3, 2026, Anthropic — the San

Overview and Investment Focus Catalio Capital Management is not a traditional venture capital firm — it is a scientist-entrepreneur network turned

Pharmaceutical licensing agreements are complex instruments designed to allocate risk between parties with fundamentally different positions. The licensor—often a